<DOC>
	<DOCNO>NCT01426633</DOCNO>
	<brief_summary>L-sarcomas represent one third adult soft tissue sarcoma ( 24 % liposarcoma 12 % leiomyosarcoma ) . Approval induction trabectedin treatment armamentarium advance and/or metastatic soft tissue sarcoma treatment failure anthracyclines and/or ifosfamide depend mainly activity L-sarcomas ( Garcia-Carbonero 2004 , Le Cesne 2005 , Demetri 2009 ) . Significant activity describe use gemcitabine especially combination gemcitabine docetaxel mainly leiomyosarcomas liposarcoma ( Maki 2007 ) . However , combination gemcitabine docetaxel associate significant toxicity . Pulmonary toxicity refractory peripheral oedema common severe adverse event . The aim present phase I study examine safety data promise treatment combination gemcitabine trabectedin L-sarcomas .</brief_summary>
	<brief_title>Combination Therapy Gemcitabine Trabectedin L-sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Patients histologically confirm Lsarcomas ( leiomyosarcoma liposarcoma ) Measurable disease accord RECIST 1.1 Any treatment line except adjuvant setting : evidence primary metastatic situation disease progression within last 6 month ( base RECIST 1.1 ) compute tomography magnetic resonance image Any prior treatment possible Age &gt; = 18 year WHO PS = &lt; 1 Effective contraception study medication 3 month treatment discontinuation Signed informed consent form Surgical intervention &lt; 4 week Pregnancy lactation Known allergic reaction trabectedin gemcitabine one components The following laboratory value : Absolute neutrophil count &lt; 1.5 x 103/mm3 Platelets &lt; 100.000/mm3 Hb &lt; 9 g/dL Serum creatinine &gt; = 2.5 mg/dl SGOT and/or SGPT and/or alkaline phosphatase and/or CPK &gt; 2.5 x ULN Total bilirubin &gt; 1 x ULN except case Gilbert 's syndrome Participation another study ( four week study ) Prior malignancy apart completely resect basal cell carcinoma skin carcinoma situ uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>L-sarcomas</keyword>
</DOC>